Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much. And my clock was a little early, so I will take a slow start here. But um, so welcome to the first quarter result. As our headline indicates, we think one of the main items for this quarter is this is the first real quarter where we can show that our guidance and our monitoring of our underlying profitability is actually correct. And we had some significant non-recurring expenses during 2023 and early in the beginning of 2023 and in 2022. And now here in the first quarter, a lot of these expenses have gone away. So we have seen the EBITDA improving compared to last year with 57 million Swedish krona, which is very much in line with our guidance and actually a little better than I think both we and the market had expected. However, this quarter also had a mixed bag because our Zubsolv sales and our comeback to that was not fully meeting our expectations. But I believe there are some good explanations for that. And on top of that, we have an R&D development where some have gone very well and others we have some small setbacks, but I think they are manageable. But that takes them into the conference. And uh. I will present today with a team who will go through the financials of the company, and I will end up with the future drivers of the company. But first, a little highlight of our key achievements for the year or for the first quarter. So I said we had a positive EBITDA with 16 million Swedish. And this is a quite good result, particularly internally based on the Zubsolv sales where we saw Zubsolv had significant destocking. And I will come back to that shortly. But also in looking at the comparator year, last year we had a first stocking from a core. So last year there was higher sales in Europe due to our supply to a core there. Right now, using the supply that we've sent to them earlier. And therefore we didn't see that come back in this quarter. But of course we expect sales to recover coming again in future quarters. So the Zubsolv decline was very much due to a destocking. And we have seen this slight underlying development and demand. But looking at, for example, sales to pharmacies, we actually had a positive trend in the first quarter. So the price increase we had in the beginning of the year is definitely helping us from a sales perspective, but we are not in control of the inventory levels at the wholesalers. And in this quarter, we had a quite unusual situation, which lowered the inventory quite significantly. And I will come back to that in more detail. Our costs are down 31% from the first quarter last year. That puts us quite good ahead of our guidance of 530 million, uh, for depreciation across the company. So we are in a good situation. On the cost side, we did during the quarter refinance our corporate bond. We did that for the first time under the sustainability framework. What I was quite pleased to see was that it was nearly oversubscribed by 100%. And we had a lot of new investors coming in, particularly from international sources, both from the US and continental Europe. Uh, our FDA review, uh, with 1 to 4 is going well on many accounts. Our review of our supply chain has been completed with the external manufacturer. It appears to have gone well. However, there are some questions that we've received recently from the FDA around the use of the device and the instructions for use that indicate that we need to go back and complement our applications, and if that is the case, that will drive a delay. But we believe that this can be done within the timeframe we have guided about before, which has been 10 to 13 months and a launch late in 2024 or early 2025. So while it's a little setback, it is something that we had built into our guidance previously. Our partnership with SOBI, which we today can say is one of the companies we worked with last year on a feasibility study we have worked on the partnership or collaboration with SOBI, and advanced it now into a more formal partnership where we are testing their molecule in AmorphOX on several different dimensions. We have also started a new collaboration with a vaccine company, where we're testing one more vaccine on a more focused scale. We believe that AmorphOX is quite well suited for vaccines. So this is important for us to generate data on this. And we are quite pleased to start up a new collaboration with a vaccine company to test a different type of vaccine. We have tested other vaccines in the platform before with good results, but this is a new type of test. Seems that we will test that takes us to our US commercial update. So there was a little uniqueness during this quarter that has had, and actually starting last year, some of it that has had an impact on Zubsolv. The first and most significant for this individual quarter is that we did see a quite significant decline in inventory from the large wholesalers in February and March, and when they are declining the whole inventory, that means that we don't sell to the wholesalers. What is unique is that we haven't seen the same change in demand. We haven't seen the same change in sales to pharmacies, and we have seen this abnormal decline. It's actually reported from other companies active in the same areas. We are with controlled substances have also seen a decline in the same period of time. So we think this is a little more systemic, probably more focused on controlled substances. But we have seen a quite unusual development in the first quarter, which of course has a direct impact on Zubsolv as we report our sales to wholesalers. Another thing that has happened, which is a real trend break starting last summer, we have seen the otherwise main driver of growth has been Medicaid for many years. But during last summer we saw the growth slowing down and in Q3 we started to see Medicaid decline. And this has accelerated into a quite rapid decline in Medicaid here in the first quarter, with nearly 10%. In parallel, we have seen a growth in the commercial sector. So we've seen this disenrollment with Medicaid for the last two, say, three quarters, where more than 20 million people have left Medicaid. And this, we believe, is very much connected to Covid, where we saw an increase in enrollment in Medicaid and people are now leaving Medicaid. And also, I believe it's tightly connected to the unemployment situation in the US, where the unemployment rates are very low, meaning that more people are getting jobs and can then obtain commercial insurance. This has a significant impact on the market dynamics. As we see, the largest segment is declining by nearly 10%. In parallel, we see the commercial segment increasing by the same number. Much of the increase in the commercial segment is due to Medicaid patients transitioning to commercial insurance. But we also see right now in the commercial segment and Medicare where we see some growth. The third thing that happened in the quarter is an incident on February 20th, in the middle of the week, when we saw the largest decline in inventory due to an abnormal inventory situation. UnitedHealth Group had its subsidiary, Change Health, which is managing the claims processes between physicians, patients, and pharmacists. They experienced a ransomware attack, which meant that many physicians did not get paid for the patients they saw; pharmacies were also not paid for the pharmaceuticals, and we believe this has had some impact on some physicians. We definitely know some physicians did not take in the same amount of patients. It's very hard to pinpoint exactly where the issues are, but it does coincide with some of the changes we've seen in the market, for example, in the inventory, and Change Health manages about a third of the claims in the US as a subsidiary. So it's by far the largest claims processing center that has been impacted by this cyberattack. So coming back to Zubsolv and the sales, these are new numbers. We haven't shared these before. But if you look at the graph here, the green line is the stable line. If you have different coloring, that represents the sales to pharmacies. And we have averaged it out over four weeks. So these are not individual weeks. And you can see, the sales to pharmacies are quite stable and actually show a slight upward trend during the second half of last year and coming into the early start of this year. So, sales to pharmacies have gone quite well. And we actually, this first quarter, have seen higher sales to pharmacies than we did in the first quarter last year. That would normally be followed by sales to wholesalers at the same level, but because over time those two numbers of course have to be exactly the same. So we need to sell to the wholesalers what they sell to pharmacies. But if you look at the dip that we see here in February and March, there's a significant dip in our sales to wholesalers, which has not been followed so far by an increase in the sales to wholesalers; of course, this is not something you can see continuing down. So it needs to normalize over time. And we are seeing right now, here in the second quarter, that the sales to pharmacies and to wholesalers are much more aligned than they were during these few weeks in February when we saw this significant drop in sales to wholesalers. In sales to wholesalers. And just for comparison, you can see last year we had a much more normal trend where I included the numbers for December; you can see there was an increase in December in both sales to wholesalers and also sales to pharmacies. And that is followed by, in the early Q1, as we saw a slight increase in December in sales to pharmacies. We see sales to pharmacies dipping a little further and then coming back up. But we have never seen that kind of adjustment we saw here in the first quarter. And again, this is not unique to Orexo. We have seen that in other companies' quarterly reports as well. So, a unique situation. But it will normalize. And that gives us confidence to say that we believe that our sales in the next quarters will be better than what we reported here in the first quarter. Zubsolv sales in general, we continue to see quite good development in Medicaid, where we have outperformed the market this quarter. As you just said in the beginning, Medicaid has actually declined quite dramatically by 9% compared to last year, whereas we are seeing a year-over-year of about 0%. So, we don't grow, but we're not losing. And our driver in Medicaid is definitely our new contracts, where we continue to see very good growth in New York, which is actually now passing our first-year anniversary. That was from December last year. Kentucky, same thing. Also double-digit growth. And Indiana, where we actually see an accelerating increase last quarter. It's 196%. But now we're actually seeing more than a 200% increase in Indiana, where we received reimbursement in July last year. We have increased the prices by 4% from January 1st. So that's something that in sales to pharmacies and wholesalers will impact positively. Overall, the market continues with relatively low growth. It's just below 3%. And that is really right now we see similar decline percentage-wise in Medicaid as we see growth in commercial. But since Medicaid is a larger segment, the growth in commercial is not good enough to drive it up. But we also see good numbers on Medicare, which is growing. Medicaid remains the largest segment in the space right now. This is a mental health program. It is a difficult market. And, uh, while I see a significant need for this, it's a view that is shared by the Centers for Medicaid Services (CMS). Uh, we have not seen any scalable solution on the reimbursement and distribution, and that is a problem for Orexo. So it's also a problem for other parties. We could drive sales. But what we've seen previously is when we did start to see some sales, the costs needed to drive sales were not feasible in the long run. We had to invest many more dollars for the sales that we got out. So we have decided to right now approach this in a very cost-conscious way, where we continue working with pilots and we're only pushing expenses when we see that we will have some traction in the market. So in Veterans Affairs, where we have been reimbursed since the 1st of January, we are now working together with an external vendor to start some pilot programs. Uh, we are also focusing more on media, but could include some of the other digital therapies. We are collaborating with leading healthcare providers in several states where we have submitted shared grant applications to these opioid abatement funds, which are now more than $50 billion, to see if we can start programs where we integrate, in particular, our digital health solutions to improve treatment of opioid use disorder. But we continue to approach this in a very cost-conscious way. It's a very small team that will work with that right now. And we are actively working together with the Center for Medicaid Services to see if we can establish a reimbursement model. And if that comes into place and we can see that there are opportunities, we would be ready to invest more into the market. But before we see that, we are holding back on our expenses in this space, that takes us to our products under development and starting with AmorphOX, uh, and our new collaboration. So we did start a collaboration with SOBI early this year, where we continued the work we did last year with them to optimize the formulation work, to extend the stability studies to see that we can, with the formulation work we are doing, get more stability data. We are also looking together with SOBI on what is the optimal route of administration. How are we going to use our amorphous powder in the best way on that molecule. So a good collaborative partnership. But we are still in an early stage. But of course, something where we expect if this materializes in a good way, it will evolve into a more. Normal licensing and co-development partnership. Then we started up a new collaboration with a vaccine company, where we are testing AmorphOX on a new vaccine to again strengthen our documentation and understanding of how AmorphOX could be used on vaccines. OX124. As I said, we have some good, promising results. We never know the outcome before we have received the final decision by the FDA. So we have conducted an audit of our external suppliers. There are always observations, but right now we believe that it was completed with good results. But what we have received, and this is basically within more or less as we speak, we have received some inquiries and questions from the FDA regarding the instructions for use. And this is back to what we can call human factor studies. So we need to show that the actual users, or actually not the people who get prescribed, but a bystander on the street, need to understand exactly how they're going to use the product. And here, the FDA had some observations and comments on our suggested instructions for use. And they also asked us to make changes to the device to improve the instructions for a particular bystander. And this is something we are implementing as we speak. And what we can see before we get data. This will push the date to 15th of July. Most likely it won't be in jeopardy. We haven't received any final decision from the FDA, but we are being transparent, looking into the questions we received, we expect this could lead to a delay. However, it's not unexpected as we've seen similar situations for essentially all other rescue medications that have been approved within a timeframe of ten months. So this is not completely surprising. And this is something that we have included in the guidance when we mentioned seeing 10 to 13 months and we still, based on what we have right now, believe that if everything goes well with these updates, we could launch late this year or early 2025, which we have been discussing with the FDA. We said that in our last quarterly report, we have now received the feedback from the FDA on our briefing book, where we outlined our clinical development program. This is, of course, something we now bring into the partner discussions that we have ongoing, and it had been anticipated in the discussions we've had, because this provides clarity about the development costs that you have to expect for the program. We presented the results from week 640 at the RI annual meeting. So this is the largest meeting with an allergy focus in the US. And we received a lot of spontaneous, positive feedback on the unique properties of 640, which gives us more confidence that we have a product that has meaningful differentiation in this market. On OX124, just to remind us this is still coming, we hope late this year or early next year from a launch perspective, and it is a high-dose naloxone product. What is unique is the powder basis where we have seen before that our bioavailability is very high, but we also believe that the stability of the product makes it important, particularly in certain regions, for example, being a powder, you are not subject to being frozen. So if you're liquid and you get into freezing temperatures, the product will freeze and not be usable. But OX124 being a powder, we have tested our powder down to -18°C and it still works nicely without any impact on the functionality of the product. The market that we are entering is very dynamic, and part of our go-to-market strategy has always been to ensure we have people in place who understand the market. And I'm very pleased to say here, from May 1st, we have a commercial lead starting in the US who will lead the commercialization of OX124. She has worked previously with the leading brand in the market. She has been working with this rescue market for several years. She's both been working with a product in the market, and also been looking into new product developments for the market. So she has been an integral part of this opioid rescue medication market for several years. And I can say already now, after a few days, we are receiving a lot of positive input from our newest employee in the US. That takes us to the financial and legal overview, and I will let Fredrik take over the presentation.
Thank you, Nikolaj. So on page 16, we look at our revenue and start by focusing on the top part of the page. You can see our total revenue in Q1 amounted to $139 million of that revenue, Obvious Zubsolv within the US commercial market is the main contributor with $129 million for the quarter, which is down year over year by 8%. Now, the main explanation for that decline is the higher wholesaler destocking effect, which, as Nikolaj explained earlier, is a normal seasonal effect. In Q1, after an inventory buildup in Q4 the previous year, that usually normalizes the next quarter. But this year, the destocking was quite substantial and was just partially offset by a favorable payer mix. Then the impact from a weaker USD exchange rate was also negative in the quarter. Now, in relation to Zubsolv ex-US revenues in Q1, from supply of tablets to our partner Accord, the reason for the major difference in revenues compared to Q1 last year is the previous inventory buildup at Accord that had a very positive effect on net revenue back then and this year. Also, lack of revenue is affected by the timing of deliveries to respective European markets. So the revenues we earn are royalties from Accord on their product sales, which are at a low level, reflecting still an early phase in the rollout in respective European markets. If you look at Zubsolv specifically in Q1 compared to Q4 last year, you can see in the waterfall graph on the bottom part of the page, higher wholesale in the third stocking of almost 21 million is also from a quarter over quarter perspective. The main explanation of why net revenue decreased: the demand for Zubsolv, expressed in net revenue terms, declined with the total approximately 2% as shown in the first three bars. While the market for buprenorphine naloxone grew 1% quarter over quarter. There is also a slightly favorable payer mix effect in the quarter. In conclusion, you can see in the graph that in local currency, Zubsolv net revenue decreased by approximately 12% between the quarters. Going to the next page, our P&L is very happy to show such a strong start of the year in relation to profitability or EBITDA, which in the quarter, despite lower net revenues, improved by 57 million, as Nikolaj Sørensen said, to 15.9 million compared to Q1 last year. And when doing the exercise that we usually do of adjusting for non-repeating costs, that would imply an even more positive EBITDA of 24 million SEK. Now to explain this strong result, first of all, when it comes to cost of goods sold, the majority of the 13 million is related to US commercial. Or to be more specific, that is 12.7 million. And compared to Q1 last year, we were actually able to improve our gross margin in US commercial from 89 to 90%. But now the decrease in the absolute amount of COGS since last year from 29 to 30 million, is still reflecting the lack of sale of Zubsolv tablets to record this quarter. Second of all, when you look at our operating expenses in Q1, we have significantly lower OpEx compared to Q1 last year. Following lower expenses for IP litigation coming down from 37 million to 2.3 million, we had lower expenses in US commercial or more specifically within digital mental health products, and it's a leaner organization and more cost-efficient processes. And then also within R&D and the AmorphOX study, which was finalized in Q3 last year, and together with lower development costs for OX124, that means a big save in expenses this quarter. The US dollar weakened slightly in the first quarter compared to last year, and the total FX effect on EBITDA was a positive 2 million. So in summary, OpEx came in at 131 million this quarter, which is 59 million or 31% lower than Q1 last year. Now, following US commercial as a segment, the EBITDA contribution from US business amounted to 43 million for the quarter, which is a margin of 33%. And that is slightly down from 35% last year. And finally, financial items. We have an unrealized FX impact of 2 million SEK on our cash held in US dollars, and lower costs for the old corporate bond of 7.7 million compared to last year. As a result of the purchase we made of 49 million in nominal value of the old bond. Moving to the next page on cash flow, it's observed that liquid funds, which is cash and cash equivalents, amounted to 198 million and 600 thousand by the end of Q1. That is an increase by 27 million from the end of Q4. So where does that come from? Well, following the strong EBITDA development in Q1, cash flow from operating activities before changes in working capital was positive for the quarter with 4.3 million. That's an improvement by 53 million compared to Q1 last year. Otherwise, cash flow for the quarter was heavily affected by the settlement of the first part of the refinancing of the bond that we completed in the quarter. So just a few words on that. We also issued 500 million of a four-year senior secured bond at a price of three months LIBOR plus 650 basis points, which, today, after the central bank's message, would be an interest rate of approximately 10.35% per annum. So the first part of the transaction was recognized in Q1, and that had a negative impact on changes in working capital. That's due to the fact that we prepaid for our own purchase of the new bond loan of 25 million. Now, financing activities, on the other hand, were positively impacted by the sale of $49 million worth of the old Drexel bond. So in summary, the first part of the transaction added a net of $24 million to our liquidity. The second part of the settlement will be recognized in Q2. In the cash flow, we also had investment activities of $1.2 million. And that's from investments in equipment for the development organization. And total cash flow for the period ended up at $23.2 million. And then adding the FX effect on cash of $3.8 million, that adds to the increase in cash of $27 million that I mentioned before, with interest-bearing liabilities of approximately $498 million. Our net debt at the end of Q1 was $299.8 million. I just want to mention that in the table of key figures on page 20 in the report, there is a different number for the net debt, and this will be corrected in the report published on our webpage. On the next page, our financial outlook for 2024. We put that up for the first time in the Q4 report. We stated that we expect market growth at 2 to 5%, Zubsolv net sales, in line with 2023, and US dollars OpEx below $520 million, and a positive EBITDA. Now, with the actuals presented today and the explanations given, especially on the Zubsolv net sales. We can conclude that these metrics are reaffirmed. And with that, I yield back to Nikolaj for the legal update.
Thank you very much, Fredrik. And, um, I'll of course, just refer to the financial outlook that we in Zubsolv net sales included here is, we expect to see a normalization of the inventory levels as we proceed. Right now they are with some of the wholesalers actually at the record low level, nearly a week less of inventory than we have seen historically. And when we come to the Q1 legal update, we have not seen anything on the patent dispute. It's surprising to us, to be honest, that we have not received a date for the hearing with the Court of Appeal. Uh, the Court of Appeal would normally have hearings, or they have hearings in the first week of every month. Uh, so we are now expecting that the hearing is probably coming in the early autumn, but we haven't received a date yet for when the appeal is. But we do actually see some positive development based on some recent decisions made by the Federal Court on some similar questions as have been used in the appeal by some, they have ruled in favor in another case in a way that we believe is applicable to our case also, which further strengthens our case, uh, coming to our US government investigations of Zubsolv. Um, nothing really has happened. We do receive some questions. They are still talking to some of our employees or former employees. Uh, we can see that the focus is on certain historic marketing messages and campaigns we have been running. But I will say that all of our marketing messages have been going through medical, legal, and regulatory review, and the legal review is actually done by an external lawyer. So it's very, very hard for us to see that we've done anything wrong. And we've not been presented with something where we can see, okay, this is something we should have done differently. But we are, of course, still collaborating with the authorities when they're asking for information. We are sharing that. But it is now approaching its fourth anniversary, and it's something that I would really like to see us put behind us. So, we have also reached out to see if there are opportunities to seek a settlement. And on this matter, as we are still paying a decent amount of legal fees to have this case running, we think it would be favorable for the company to put it behind us, even though that would mean that we have to do a settlement, albeit a little short on our future drivers. I will say that I'm fully aware that our share price and our value creation are not based on our ability to tighten the belt and lower our expenses. I do find it incredibly important for Orexo to show that we can tighten the belt when needed, to ensure stability for the company. We can reach positive EBITDA numbers where I would say we are very close to having our fourth consecutive quarter with positive EBITDA. We did have a little dip in the third quarter last year, but if you recall, that was when we had to pay the fee to the FDA for weeks 1 to 4. Without that, this would have been our fourth quarter with a positive EBITDA. And we see that improvement also even when we are adjusting for these non-recurring items. But what is important for the company is, of course, our top line. And to drive our top line, it's basically ensuring that our foundation soil is stabilized so that we will have good, stable, and decent development of Zubsolv moving forward. But where the real growth is supposed to come from is the pipeline; it is from the launch of OX124. So of course, any delay in the launch plan for weeks 1 to 4 is delaying that possible launch. At the same time, we can say every delay will also delay some of the expenses that we need to take around the launch of OX124, but we are seeing that the launch of new products is important to grow our commercial revenues, and we in particular have high expectations for the launch of new pharmaceuticals or digital therapies or digital mental health programs. We still think it's an interesting opportunity, but right now we see that more like an option than something we're really putting a lot of money behind to drive. Our AmorphOX technology is something that we believe can drive not only income from our own commercial operations. Associations, but also from partnerships and here particularly with biomolecules, where we believe that the AmorphOX technology is very well suited to solve some of the issues that have been seen with biomolecules in terms of stability and other delivery methods of the product. You can move from an injectable to a nasal spray, or you can take away some of the inconvenience or pain that is felt with some of the injections due to some of the preservatives that are put into the product. So, our focus is broadening the opportunity for more efficient drug delivery for biomolecules. So partnerships like the one we have with SOBI are something that we believe could be a solid long-term growth driver for the company. And then we have OX640, which again, where we have been a little in the vacuum here because of the uncertainty around the development program. But now that we have more clarity, we believe there are strengthened opportunities for us to find a partnership for OX640. OX640 is still an opportunity, in particular, based on the feedback we got from physicians at a US conference, which gave us even more confidence that we have a product that is meaningfully differentiated in the eyes of the physicians and patients. So summarizing, growing commercial revenues and profit contributions is important. And we see that will happen through capitalizing on our drug delivery technology and of course, improving access to treatment for all of our products. So for us, growth is important. But while we're waiting for these next growth drivers, it is incredibly important to secure a strong profitability and balance sheet or strengthening the profitability from where we are right now. With that, I will leave it over to questions and thank you for your attention.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Ned Brown from Prairie Capital. Please go ahead.
Um, Nicolaj, I don't have a question, but I have two pieces of news that could be relevant to Zubsolv growth. One is in South Carolina, where I live, the state is using some of their opioid settlement funds to start a mail order, um, buprenorphine pharmacy. So it'll greatly help improve, uh, distribution. And particularly in rural counties in the state, it will be a buprenorphine naloxone product, because that's what the DEA wants. So that should be operational in the fall. As I said, the state has put money behind it. The second point, um, related to Zubsolv is that the Department of Health and Human Services issued a request for grants last week, uh, to 59 states and US territories. So the states specifically have to apply for the money. It's a fairly staggering 1.48 billion USD over three years. And one of the key criteria that they have that they want to see from the states is expanded distribution of buprenorphine to people. You know, we're trying to get it. So whether it's just total numbers of people on buprenorphine or Medicaid coverage or whatever. Uh, that's a as I said, 1.48 billion USD over three years. So you might want to partner with your, your friends in New York, Kentucky, and Indiana to make sure their requests have to be in by July 1st. So that leaves less than seven weeks to get the grant requests in. So I just wanted to pass that along. I hope it's helpful.
Thank you very much, Ned. And, uh, thank you for your comment at last quarter. I know you have been in touch with our with some of my US-based colleagues. Um, and there have been some discussions about how we could leverage some of these opportunities. And I think you're putting the head on the nail here with regards to the grant money and the opioid settlement funds. And I'm pleased to hear that. Also, this kind of movement is made from a national level, national way. Uh, we are working in several states in the US. We have grants. And right now working with healthcare providers to access some of these funds, actually, by coming up with programs that could improve access to medications and other solutions. So we are working actively with this, but it's of course an area where we are a small player here. So we need to work with other partners who have direct access to the patients. And I appreciate all your comments. So thank you. Any other questions?
The next question comes from Sammy Advani from Arc Securities. Please go ahead.
Hi, guys. Thanks for taking my questions. I think I have three. So, maybe just kicking off with OX124 and the additional work that you need to complete. I'm just wondering, do you think you'll have that done before the original due date? So I guess that's question one. And still with the FDA. You mentioned in the report about completing some of the discussions regarding OX40 in the clinical trial. I'm just wondering what else is left to complete. And now, having had those discussions, do you feel more or less confident in your ability to partner that product this year? And then my final question is for Fredrik, just on the corporate bond, you mentioned that there will be a further settlement in Q2, and I'm just wondering if you could maybe take us through what the cash flow impact of that settlement will be. Thanks very much.
Okay. I will take the first two. And as you said, Fredrik, I will happily leave the last question to him. So, the first one with OX124. We knew that the area the FDA was highlighting was one where we had expected there could be significant questions from the agency. And we have worked in parallel to see what kind of mitigation strategies we have, what kind of mitigation activities we have? So we.
Have.
We have advanced the process to find a solution for this. Then the thing. So we believe we have a solution in place which could be implemented well ahead of the final PDUFA date. The thing is, we would probably need to test that in a population also. And there it actually depends a little on the timing of some of the pre-testing we're doing right now of these concepts, to see what kind of feedback we get. And I would say it's very borderline whether we'll have that ready before the PDUFA date, which is one of the reasons why we believe it could lead to a delay in the approval process. But it would be irresponsible not to have a mitigation plan. And of course, you know some of the weaknesses and strengths in your application when you send it in. And this around the human factor is a difficult one. It's something that we've seen in a lot of other rescue medications where you need to iterate. And we had some mixed results in the first study, uh, that could be an issue for the FDA and, and they came back. But in the interim, we have actually worked on the supply chain to see what we can do both on the device to make it clearer how to operate it, but also in the instructions for you. So, we were ready. But, of course, we hadn't taken the cost to test these new concepts before we knew exactly what to test on. That's coming from the questions we received basically within the last few weeks from the FDA. Oh, 640. I, I wouldn't say that for the US market we have, there's of course, other stuff you need to get from the FDA as we proceed. But this is really the critical part was around the clinical program, and we sent in a program where we. Built in some of the feedback we saw for the Rs pharma products. So we basically adjusted the clinical program we had planned initially based on the feedback they received, and we sent it to the FDA and we got it. We didn't get it. There were no changes coming back from the FDA. So in that way it was quite positive. And I think the clinical program can be done in a relatively smooth manner. It's not a very big program. So I think this is strong and it's good for the partnership. I do think that one of the things that we do receive questions from is from partners around Europe. And what are the requirements for the EMA. And that's a bit of a timing. And tactical question for us is when do we reach out to the EMA and in what way? So I think that's something that some of the partners would appreciate getting more feedback on. But the biggest market in any calculations for this is the US market. And here I think we have a quite clear pathway for what we need to do to get it approved in the US, and the team continues to work on this. I'll just say that while we were talking with partners, it's not like we're stopping the development program at Orexo. So we continue to work on it. And, um, I think this right now, we have basically what we need for these partnering discussions and that needs to continue.
So yes, the bond, I mean, it was, uh, I mean, the actual transaction was done in March and that happened to be over the quarter. Uh, so quarter ending. So, um, that's why the first part was related to our own, um, transactions on the bond, which involve selling the old bond for 9 million and acquiring the new bond of 25 million. So that's why there was a positive contribution to liquidity for the quarter; next quarter, we did acquire an additional 5 million of the bond. So, that is negative. Um, so, uh, if you compare the situation for us, we will end up with a holding of 30 million in the new bond compared to 50 million SEK in the old bond. And then we have obviously cost for the bond issue. And uh, that would be put on the balance sheet, but obviously we need to pay it now.
That's great. Thanks very much.
Any other questions?
Okay. What?
The next question comes from Claus Palin from Carnegie. Please go ahead.
Hello, and thank you for taking my questions. Um, maybe I'm just having a question. What you already have answered. But just to clarify, uh, what you got from the FDA regarding OX640, the clinical pathway forward is in line with what you have been discussing with potential partners previously.
Uh, I would say, the, um. It depends on the partner. So, um, okay, that there were, um.
That. Well.
There's one partner where I think this will come as a positive. Um, positive. So positive information.
Or.
What not, it will come. So they are aware. So this, I think, is smaller than what they had planned. Um, the other partner I spoke to had come in here after we had submitted it to the FDA. So they I think they're building the case based on what we submitted to the FDA. But there was one partner that we worked with last summer who is still part of the mix right now. And the program we have is definitely leaner than the program they were planning, but.
And, um, the future studies you need to do. They, they sort of are also in line with your timeline to get OX640 to a filing.
Uh, it.
So, so we have to. So some of it we can definitely do the studies within that timeline. But we are very interested in having a partner on board before we go into the study. So, right now I will not commit to a timeline for how we're going to run it. Um.
Perfect.
Uh, just a question about this wholesaler destocking. And, um, has this had any impact on access for Zubsolv, or other controlled substances for patients?
Uh, I.
Heard anything about.
No, but as you saw on the graph which I showed, the sales to pharmacies were actually quite stable. So we did see some of the wholesalers say part of the effect was maybe that some of the wholesalers during the second half of last year had built up a little higher inventory than what they usually have. So, we think we had two effects: first, they were a little higher when we ended the year. It's a slightly higher level. Not normally. We see that increase just before Christmas, but we didn't see that this year. But if you look across the second half of the year, there was a slight build-up starting in late Q3 and then into Q4, and then it was stable, and then they dropped down. But right now, two of the wholesalers are at very, very low levels. Um, and sales to pharmacies have been stable. And we actually asked our sales force if there are any complaints about access to the product. And we haven't heard that. So we think this.
It's.
There are many speculative reasons for this. We think we know that some of them have a more strict view on how much opioid control or controlled substances they can have in inventory. So that could be an effect that they are actually reducing the inventory of controlled substances in general. It also, we also know that at least one of them referred in their quarterly report that they had to pay money into the opioid abatement funds as part of the settlement during the first quarter. So it could be a way to free up cash that they actually reduced the inventory on some products, and the natural products to do this on are products where you have a relatively stable supply and stable demand. So Orexo has not had any single time during ten years been out of stock. So we have been able to supply them whenever they have sent the order. And I think that is important. If you want to go down in inventory, then you need to be sure that you will get supply from the supplier when needed. And since Orexo has been very stable as a supplier, I think that in one way penalizes us in this process because they're quite certain that even going down to one week less of inventory, they would still be able to supply the market. But right now, we believe that they are at an unusually low level. So we would expect some kind of normalization in the second quarter.
Okay. Perfect. And then I would like to jump to your own balance sheet and inventory. It was up during the quarter. Is this related to this effect or are there any other reasons?
Um.
Not any other reasons. I mean, that's, uh, regular operations consequences, I would say.
Okay.
So we see this as more of a normal level compared to what we saw in Q4 then.
I think in hindsight, Q4 was maybe a little higher than what we usually see. Um, but we didn't see any build-up in Q4 dramatically in, in a few weeks, which we would have done previously, as you also saw the year before. I included the numbers for December the year before. You saw some jump in December. Uh, we didn't see that this year. Um, but I would be surprised if at least two of the three large wholesalers in the US are not currently at a level which is very, very low. I would be surprised if they're not jumping up a little. Um, how much that will impact the overall inventory? I don't know, but they should continue to. To lower is unlikely. I can't see that we should have this effect coming into Q2 also that you see an even further gap. So either they normalize and we will follow the sales to pharmacies. But if you look at the curve that was much higher per week than what we reported in sales to wholesalers, if we can just stay on that level throughout Q2, that will lead to improved sales numbers. Uh, if it's a compensation that they actually increase inventory somewhat during the quarter, that will, of course, strengthen sales even further.
Perfect.
And yeah. Then my last question, um, about how you have been quite successful in lowering your opex. Uh, are we at a sort of a bottom level now or, I mean, excluding legal costs, or do you see further improvements that could be possible?
I mean, we can just conclude that, doing the math, we are well below the target. Um, but we know that other costs are entering the scene regarding some sort of commercialization efforts, preparations, like 1 to 4. Um, so, uh, I think we can't give any more guidance on that. Um, okay. But it.
Looks.
But I will say we are constantly looking for.
For.
How we can lower expenses, and that goes for everything we are reviewing. After Covid, we have fewer people in the office. So we are looking at our office space in Uppsala. We are working continuously with our cost of goods, and it's quite simple. If we can lower our expenses for subs or improve our gross margin by 1%, that translates into about 6 million in profit. So any percent that we can work on our gross profit is important. We also are looking at continuous ways that we can improve our cost of goods sold. So I don't think a cost-conscious approach is ever anything. You just need to focus. But that is of course also to free up money, to put money where we believe we can see growth. And that could be for projects in phases 1 to 4. It could be further investments into OX124 or other development programs that we want to invest in. Overall, I wouldn't expect us to come at a lower level. But if you just take the business as we are right now, I think there will be additional, uh, additional savings. But we hope to free up money that we can invest in other places.
Perfect. Very good. Um, thank you so much for taking my questions.
Thank you. So.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad.
And we received a question also from the webinar that was about digital mental health programs. Can we expect any revenues from that in the future quarters? I would say we have a decent amount of opportunities that we believe could lead to income coming from digital mental health. Some of the grant applications we have, I think, could be recognized more under 'other income' than on revenues, but it will be a positive income stream to Orexo. And of course I would just say these grants. Why are we doing that? Shouldn't they lead to revenues? The idea is, of course, that we are running projects together with healthcare providers, which, if successful, could be scaled up to a much bigger solution which would give us more ongoing business opportunities. We have several grants in several states right now. If they are successful, they would lead to income coming from digital mental health. We are also working on the VA, where we are now starting up with a new vendor who has been successful in starting digital mental health programs in some states in the US. And we will see if they can use that experience to also help us navigate the Veterans Affairs community. So we have shots on goal. But I must admit that I have been wrong before on digital mental health, so I have to be a little cautious. And what kind of guidance? I would say so much. I do believe we will get some income from digital mental health. Will it be material to our EBITDA compared to our income from Zubsolv and royalty streams? That I doubt will happen here in the next few quarters. With that, we have no further questions. And in Sweden today, I think the stock market has closed now. So it's a half day, and I'm pleased with all of you who tuned in and listened to this call. So thank you so much and have a pleasant day. Right.



















